세계의 항바이러스제 시장 : 약제 유형별, 치료제별, 최종 용도별 - 예측(2025-2030년)

The Antiviral Drugs Market was valued at USD 56.22 billion in 2023, expected to reach USD 59.84 billion in 2024, and is projected to grow at a CAGR of 6.54%, to USD 87.61 billion by 2030.

Antiviral drugs are pharmaceuticals designed to inhibit the development and spread of viral infections. Their scope encompasses several applications, including treating conditions like HIV, hepatitis, influenza, and other contagious viral diseases. The necessity for antiviral drugs arises from the need to control and prevent outbreaks, protect susceptible populations, and ensure public health safety. In the context of COVID-19 and other emerging viral threats, the demand for effective antiviral medications has surged, underscoring their critical role in healthcare. The end-use scope includes hospitals, clinics, research laboratories, and home care settings, where antiviral drugs serve both therapeutic and preventive purposes.

Key factors driving the market growth include ongoing research and technological advancements, rising awareness about viral infections, and increasing government and private sector investments. Robust pipeline drugs and the frequent emergence of new viral strains present potential opportunities for market expansion. Companies can capitalize on these by accelerating drug development processes and adapting to rapid changes in viral dynamics. However, the market faces limitations such as high costs, regulatory challenges, and the potential for viral resistance, which can impede widespread adoption and accessibility of antiviral treatments.

Innovation opportunities lie in personalized medicine, where drugs are tailored to individual patient needs, and in developing broad-spectrum antivirals that can target multiple viruses simultaneously. Additionally, leveraging artificial intelligence and machine learning for drug discovery could accelerate the identification of effective compounds. The antiviral drug market is dynamic, characterized by continuous R&D endeavors and rapid technological advancements. Companies must maintain agility to adapt to changing regulatory standards and emerging health threats. By investing in innovative solutions and strategic collaborations, businesses can drive growth while meeting the pressing need for effective antiviral therapies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antiviral Drugs Market

The Antiviral Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing occurrence of viral diseases such as HIV, hepatitis, and influenza
  • Rising government and private sector expenditure in the development of antiviral drugs
  • Growing number of antiviral programs and campaigns to increase customer awareness
• Market Restraints
  • High cost of antiviral drug treatment and concerns of patent expiration
• Market Opportunities
  • Research and development in the production of vaccines for numerous viral infections and diseases
  • Extensive formulations to develop HIV vaccines
• Market Challenges
  • Prevalence of alternative therapy such as homeopathy

Porter's Five Forces: A Strategic Tool for Navigating the Antiviral Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antiviral Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antiviral Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antiviral Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antiviral Drugs Market

A detailed market share analysis in the Antiviral Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antiviral Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antiviral Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antiviral Drugs Market

A strategic analysis of the Antiviral Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antiviral Drugs Market, highlighting leading vendors and their innovative profiles. These include Abacus Bioscience Inc., Abbott Laboratories, AbbVie Inc., Antiva Biosciences, Inc., AstraZeneca PLC, Aurobindo Pharma, Bristol-Myers Squibb Company, Chimerix Inc., Cipla Limited, Dr. Reddy's Laboratories Ltd., ENYO Pharma SA, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., and Novartis AG.

Market Segmentation & Coverage

This research report categorizes the Antiviral Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Branded Drugs and Generic Drugs.
• Based on Therapeutics, market is studied across Acquired Immunodeficiency Syndrome Therapeutics, Hepatitis (B & C) Therapeutics, Herpes Therapeutics, Influenza Therapeutics, and Pneumonia.
• Based on End Use, market is studied across Ambulatory Surgical Centres, Clinics, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing occurrence of viral diseases such as HIV, hepatitis, and influenza
    • 5.1.1.2. Rising government and private sector expenditure in the development of antiviral drugs
    • 5.1.1.3. Growing number of antiviral programs and campaigns to increase customer awareness
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of antiviral drug treatment and concerns of patent expiration
  • 5.1.3. Opportunities
    • 5.1.3.1. Research and development in the production of vaccines for numerous viral infections and diseases
    • 5.1.3.2. Extensive formulations to develop HIV vaccines
  • 5.1.4. Challenges
    • 5.1.4.1. Prevalence of alternative therapy such as homeopathy
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antiviral Drugs Market, by Drug Type

• 6.1. Introduction
• 6.2. Branded Drugs
• 6.3. Generic Drugs

7. Antiviral Drugs Market, by Therapeutics

• 7.1. Introduction
• 7.2. Acquired Immunodeficiency Syndrome Therapeutics
• 7.3. Hepatitis (B & C) Therapeutics
• 7.4. Herpes Therapeutics
• 7.5. Influenza Therapeutics
• 7.6. Pneumonia

8. Antiviral Drugs Market, by End Use

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centres
• 8.3. Clinics
• 8.4. Hospitals

9. Americas Antiviral Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Antiviral Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Antiviral Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abacus Bioscience Inc.
• 2. Abbott Laboratories
• 3. AbbVie Inc.
• 4. Antiva Biosciences, Inc.
• 5. AstraZeneca PLC
• 6. Aurobindo Pharma
• 7. Bristol-Myers Squibb Company
• 8. Chimerix Inc.
• 9. Cipla Limited
• 10. Dr. Reddy's Laboratories Ltd.
• 11. ENYO Pharma SA
• 12. F. Hoffmann-La Roche AG
• 13. Gilead Sciences, Inc.
• 14. GlaxoSmithKline PLC
• 15. Johnson & Johnson
• 16. Merck & Co., Inc.
• 17. Novartis AG